CH-223191

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Augusta University and 6 more

Animals1

Outcomes

Oxidative stress and ROS signalling

downin mice1

1 study

CH-223191 decreases oxidative stress and ROS signalling in mice.
“CH-223191 treatment improved cortical bone and showed beneficial effects in skeletal muscle, including reducing oxidative stress as compared with VEH-treated animals.”
AnimalsCompared with vehicle-treated C57BL/6 miceskeletal muscle3.3 mg/kg, 3 days/week12 weeksmale and females
Inhibition of AhR improves cortical bone and skeletal muscle function via preservation of neuromuscular junctions
JCI insight15 Jul 2025

More on Oxidative stress and ROS signalling